GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bicara Therapeutics Inc (NAS:BCAX) » Definitions » FCF Margin %

BCAX (Bicara Therapeutics) FCF Margin % : 0.00% (As of Jun. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Bicara Therapeutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Bicara Therapeutics's Free Cash Flow for the six months ended in Jun. 2024 was $-27.52 Mil. Bicara Therapeutics's Revenue for the six months ended in Jun. 2024 was $0.00 Mil. Therefore, Bicara Therapeutics's FCF Margin % for the quarter that ended in Jun. 2024 was 0.00%.

As of today, Bicara Therapeutics's current FCF Yield % is -4.69%.

The historical rank and industry rank for Bicara Therapeutics's FCF Margin % or its related term are showing as below:


BCAX's FCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -145.32
* Ranked among companies with meaningful FCF Margin % only.

Bicara Therapeutics FCF Margin % Historical Data

The historical data trend for Bicara Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bicara Therapeutics FCF Margin % Chart

Bicara Therapeutics Annual Data
Trend Dec22 Dec23
FCF Margin %
- -

Bicara Therapeutics Semi-Annual Data
Dec22 Jun23 Dec23 Jun24
FCF Margin % - - - -

Competitive Comparison of Bicara Therapeutics's FCF Margin %

For the Biotechnology subindustry, Bicara Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bicara Therapeutics's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bicara Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Bicara Therapeutics's FCF Margin % falls into.


Bicara Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Bicara Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-46.214/0
= %

Bicara Therapeutics's FCF Margin for the quarter that ended in Jun. 2024 is calculated as

FCF Margin=Free Cash Flow (Q: Jun. 2024 )/Revenue (Q: Jun. 2024 )
=-27.518/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bicara Therapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Bicara Therapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Bicara Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bicara Therapeutics Inc (NAS:BCAX) » Definitions » FCF Margin %
Comparable Companies
Traded in Other Exchanges
N/A
Address
116 Huntington Avenue, Suite 703, Boston, MA, USA, 02116
Website
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.